WUGEN Announces Presentations at American Society of Hematology Annual Meeting
ST. LOUIS, Nov. 1, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an…
Read More